Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 401-408

  Perola, Emanuele ^b   Xu, Kun ^b   Kollmeyer, Thomas M ^b   Kaufmann, Scott H ^a,b   Prendergast, Franklyn G ^a,b   Pang, Yuan Ping ^a,b,c  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; MATRIX METALLOPROTEINASE; METALLOPROTEIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BINDING AFFINITY; CANCER; CARDIOVASCULAR DISEASE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; VIRTUAL REALITY;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BINDING SITES; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; MODELS, MOLECULAR; RATS; TUMOR CELLS, CULTURED; ZINC;

EID: 0034628541     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990408a     Document Type: Article

References (62)

1. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-82.
2. Shoichet, B. K.; Stroud, R. M.; Santi, D. V.; Kuntz, I. D.; Perry, K. M. Structure-based discovery of inhibitors of thymidylate synthase. Science 1993, 259, 1445-50.
3. Rutenber, E.; Fauman, E. B.; Keenan, R. J.; Fong, S.; Furth, P. S.; Ortiz de Montellano, P. R.; Meng, E.; Kuntz, I. D.; DeCamp, D. L.; Salto, R. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J. Biol. Chem. 1993, 268, 15343-6.
4. Zheng, Q.; Kyle, D. J. Computational screening of combinatorial libraries. Bioorg. Med. Chem. 1996, 4, 631-8.
5. Gschwend, D. A.; Good, A. C.; Kuntz, I. D. Molecular docking towards drug discovery. J. Mol. Recognit. 1996, 9, 175-86.
6. Finn, P. W. Computer-based screening of compound databases for the identification of novel leads. Drug Discovery Today 1996, 1, 363-370.
7. Horvath, D. A virtual screening approach applied to the search for trypanothione reductase inhibitors. J. Med. Chem. 1997, 40, 2412-23.
8. Toyoda, T.; Brobey, R. K. B.; Sano, G.; Horii, T.; Tomioka, N.; Itai, A. Lead Discovery of Inhibitors of the Dihydrofolate Reductase Domain of Plasmodium Falciparum Dihydrofolate Reductase-Thymidylate Synthase. Biochem. Biophys. Res. Commun. 1997, 235, 515-519.
9. Olson, A. J.; Goodsell, D. S. Automated docking and the search for HIV protease inhibitors. Sar. Qsar. Environ. Res. 1998, 8, 273-85.
10. Walters, W. P.; Stahl, M. T.; Murcko, M. A. Virtual screening -an overview. Drug Discovery Today 1998, 3, 160-178.
11. Toney, J. H.; Fitzgerald, P. M. D.; Groversharma, N.; Olson, S. H.; May, W. J.; Sundelof, J. G.; Vanderwall, D. E.; Cleary, K. A.; Grant, S. K.; Wu, J. K.; Kozarich, J. W.; Pompliano, D. L.; Hammond, G. G. Antibiotic Sensitization Using Biphenyl Tetrazoles As Potent Inhibitors of Bacteroides Fragilis Metallo-Beta-Lactamase. Chem. Biol. 1998, 5, 185-196.
12. Park, H. W.; Boduluri, S. R.; Moomaw, J. F.; Casey, P. J.; Beese, L. S. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997, 275, 1800-4.
13. Gomis-Ruth, F. X.; Maskos, K.; Betz, M.; Bergner, A.; Huber, R.; Suzuki, K.; Yoshida, N.; Nagase, H.; Brew, K.; Bourenkov, G. P.; Bartunik, H.; Bode, W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997, 389, 77-81.
14. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-4.
15. ACD: http://www.mdli.com/cgi/dynamic/product.html?uid= &key=&subname=chemsourcing&id=17, 1999.
16. Fu, H. W.; Beese, L. S.; Casey, P. J. Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase. Biochemistry 1998, 37, 4465-72.
17. Roe, R. R.; Pang, Y. P. Zinc's exclusive tetrahedral coordination governed by its electronic structure. J Mol. Model. 1999, 5, 134-140.
18. ElYazal, J.; Pang, Y.-P. Ab initio Calculations of Proton Dissociation Energies of Zinc Ligands: hypothesis of Imidazolate as Zinc Ligand in Proteins. J. Phys. Chem. B 1999, 103, 8773-8779.
19. Pang, Y.-P. Novel Zinc Protein Molecular Dynamics Simulations: Steps Toward Antiangiogenesis for Cancer Treatment. J. Mol. Model. 1999, 5, 196-202.
20. Xu, K.; Perola, E.; Prendergast, F. G.; Pang, Y.-P. Models of Ternary Complexes for Nonpeptidic Farnesyltransferase Inhibitors: Insights into Structure-Based Design of Potential Anticancer Therapeutics. J. Mol. Model. 1999, 5, 203-217.
21. Gibbs, J. B.; Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 143-66.
22. Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260, 1934-7.
23. Prendergast, G. C.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of rastransformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 1994, 14, 4193-202.
24. Sebti, S. M.; Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 1997, 74, 103-14.
25. Njoroge, F. G.; Taveras, A. G.; Kelly, J.; Remiszewski, S.; Mallams, A. K.; Wolin, R.; Afonso, A.; Cooper, A. B.; Rane, D F.; Liu, Y. T.; Wong, J.; Vibulbhan, B.; Pinto, P.; Deskus, J. Alvarez, C. S.; del Rosario, J.; Connolly, M.; Wang, J.; Desai, J. Rossman, R. R.; Bishop, W. R.; Patton, R.; Wang, L.; Kir schmeier, P.; Bryant, M. S.; Nomeir, A. A.; Lin, C.-C.; Liu, M.; McPhail, A. T.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K.(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2- b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J. Med. Chem. 1998, 41, 4890-902.
26. Rawls, R. L. Puzzling Promise Of Protein Prenylation. Chem. Eng. News 1998, 67-9.
27. Chen, W. J.; Moomaw, J. F.; Overton, L.; Kost, T. A.; Casey, P. J. High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc. J. Biol. Chem. 1993, 268, 9675-80.
28. Pang, Y. P.; Brimijoin, S. Supercomputing-Based Dimeric Analogue Approach For Drug Optimization. Parallel Comput. 1998, 24, 1557-1566.
29. Koshland, D. E. The key-lock theory and the induced fit theory. Angew. Chem., Int. Ed. Engl 1995, 33, 2375-2378.
30. Pang, Y. P.; Kozikowski, A. P. Prediction of the binding sites of huperzine a in acetylcholinesterase by docking studies. J. Comput.-Aided Mol. Design 1994, 8, 669-681.
31. Pang, Y. P.; Kozikowski, A. P. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the sysdoc program. J. Comput.-Aided Mol. Des. 1994, 8, 683-693.
32. Raves, M. L.; Harel, M.; Pang, Y.-P.; Silman, I.; Kozikowski, A. P.; Sussman, J. L. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 1997, 4, 57-63.
33. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297-307.
34. Pang, Y.-P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646-9.
35. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz Jr., K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
36. McCammon, J. A.; Gehn, B. R.; Karplus, M. Dynamics of foled proteins. Nature 1977, 267, 585.
37. vanGunsteren, W. F.; Berendsen, H. J. C. Computer simulation of molecular dynamics: methodology, applications, and perspectives in chemistry. Angew. Chem., Int. Ed. Engl. 1990, 29, 992.
38. Cramer, R. D.; Patterson, D. E.; Clark, R. D.; Soltanshahi, F.; Lawless, M. S. Virtual Compound Libraries - a New Approach to Decision Making in Molecular Discovery Research. J. Chem. Inf. Comput. Sci. 1998, 38, 1010-1023.
39. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deana, A. A.; et al. Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J. Med. Chem. 1994, 37, 725-32.
40. Ryde, U. The Coordination Chemistry of the Structural Zinc Ion in Alcohol Dehydrogenase Studied By Ab Initio Quantum Chemical Calculations. Ear. Biophys. J. 1996, 24, 213-221.
41. Sinensky, M.; Fantle, K.; Dalton, M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. 1994, 54, 3229-32.
42. Kilic, F.; Dalton, M. B.; Burrell, S. K.; Mayer, J. P.; Patterson, S. D.; Sinensky, M. In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease. J. Biol. Chem. 1997, 272, 5298-304.
43. Adjei, A. A.; Erlichman, C.; Davis, J. N.; Cutler, D. L.; Sloan, J. A.; Marks, R. S.; Hanson, L. J.; Svingen, P. A.; Atherton, P.; Bishop, W. R.; Kirschmeier, P.; Kaufmann, S. H. A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity. Submitted.
44. Kaufmann, S. H.; Svingen, P. A.; Gore, S. D.; Armstrong, D. K.; Cheng, Y. C.; Rowinsky, E. K. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 1997, 89, 2098-104.
45. Smith, P. K.; Krohn, R. I.; Hermanson, G. T.; Mallia, A. K.; Gartner, F. H.; Provenzano, M. D.; Fujimoto, E. K.; Goeke, N. M.; Olson, B. J.; Klenk, D. C. Measurement of protein using bicinchoninic acid [published erratum appears in Anal. Biochem. 1987, 163(1, May 15), p 279]. Anal. Biochem. 1985, 150, 76-85.
46. Kaufmann, S. H. Additional Members of the Rat Liver Lamin Polypeptide Family. J. Biol. Chem. 1989, 264, 13946-13955.
47. MDL: http://www.mdli.com, 1999.
48. Gasteiger, J.; Marsili, M. A new model for calculating atomic charges in molecules. Tetrahedron Lett. 1978, 34, 3181-3184.
49. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3222.
50. SYBYL: Tripos Associates, Inc.: 1699 S. Hanley Road, Suite 303, St. Louis, MO 63144, 1997.
51. Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium. J. Phys. Chem. 1996, 100, 19824-39.
52. Cramer, C. J.; Truhlar, D. G. General Parametrized SCF Model for Free Energies of Solvation in Aqueous Solution. J. Am. Chem. Soc. 1991, 113, 8305-8311.
53. MDDR: http://www.mdli.com/dats/pharmdb.html, 1999.
54. Sunazuka, T.; Hirose, T.; Tian, Z. M.; Uchida, R.; Shiomi, K.; Harigaya, Y.; Omura, S. Syntheses and Absolute Structures of Novel Protein Farnesyltransferase Inhibitors, Kurasoins A and B. J. Antibiot. 1997, 50, 453-455.
55. CSD: http://www.ccdc.cam.ac.uk, 1999.
56. NCI-3D-database: http://dtp.nci.nih.gov, 1999.
57. Long, S. B.; Casey, P. J.; Beese, L. S. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry 1998, 37, 9612-8.
58. Dunten, P.; Kammlott, U.; Crowther, R.; Weber, D.; Palermo, R.; Birktoft, J. Protein farnesyltransferase - structure and implications for substrate binding. Biochemistry 1998, 37, 7907-7912.
59. Strickland, C. L.; Windsor, W. T.; Syto, R.; Wang, L.; Bond, R.; Wu, Z.; Schwartz, J.; Le, H. V.; Beese, L. S.; Weber, P. C. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry 1998, 37, 16601-16611.
60. Strickland, C. L.; Weber, P. C.; Windsor, W. T.; Wu, Z.; Le, H. V.; Albanese, M. M.; Alvarez, C. S.; Cesarz, D.; del Rosario, J.; Deskus, J.; Mallams, A. K.; Njoroge, F. G.; Piwinski, J. J.; Remiszewski, S.; Rossman, R. R.; Taveras, A. G.; Vibulbhan, B.; Doll, R. J.; Girijavallabhan, V. M.; Ganguly, A. K. Tricyclic farnesyl protein transferase inhibitors: Crystallographic and calorimetric studies of structure - activity relationships. J. Med. Chem. 1999, 42, 2125-2135.
61. Furfine, E.; Leban, J.; Landavazo, A.; Moomaw, J.; Casey, P. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 1995, 34, 6857-6862.
62. Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J. J.; Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 1993, 268, 18415-8.